Oral Therapies, Autoinjectors and Dosing/Administration
in the Changing MS Management Paradigm:
Overcoming Barriers to Treatment

New Horizons in the Treatment and Management of Multiple Sclerosis is a 7-part live webinar
series that will provide attendees with the latest information in MS management.

This is Part 3 of the series focusing on Oral Therapies, autoinjectors and Dosing/Administration
in the Changing MS Management Paradigm

This activity is an archive from the webinar held January 11, 2017

This activity is valid from March 15, 2017 to March 31, 2019

Instructions for CME/CNE: Listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.  To print or save your certificate, you will need to click on the “download” button and either print or save.
 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This educational activity is supported by educational grants from
AbbVie, Bayer HealthCare, Biogen, Novartis Pharmaceuticals and Sanofi Genzyme

Description:
Although there is still no cure for MS, many advances in MS treatment have arrived in recent years, allowing patients to manage these symptoms and improve their quality of life. Lack of early implementation of appropriate interventions based on a balance of efficacy and safety of current and emerging therapies, updated guidelines and the newest clinical data leads to inadequate control of MS. This session will provide attendees with an updated review of therapies, dosing methods, overcoming potential barriers and how these affect patient adherence.

Upon Completion of this activity, participants will be able to:

  • Discuss barriers to treatment in management multiple sclerosis and strategies to overcome those barriers

  • Analyze the role of autoinjectors in the management of relapsing MS and discuss which patients could benefit from their use

  • Discuss oral therapies and their effect on MS efficacy and patient adherence in MS

  • Examine how dosing and administration of new therapies can affect patient adherence and outcomes
     

Faculty: George Hutton, MD
Medical Director
Maxine Mesinger MS Comprehensive Care Center
Baylor College of Medicine
McNair Campus

Disclosure:

Dr. Hutton previously served as an advisor to Genentech. He currently receives research support from Biogen Idec, Genzyme, Hoffman, LaRoche, Medimmune, and Opexa. His presentation has been peer reviewed for bias.
 
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jacquelyn Smith, RN, BSN, MA, CMCN has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

The National Association of Managed Care Physicians designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Nurses who complete this activity and turn in a validation form will receive up to 1 credit in continuing nursing education.

The American Board of Managed Care Nurses has approved this activity for a maximum of 1 contact hour towards CMCN recertification.

This educational activity is supported by educational grants from
AbbVie, Bayer HealthCare, Biogen, Novartis Pharmaceuticals and Sanofi Genzyme

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue